Role of miRNA in drug-induced hepatic injury
Keywords:miRNA, hepatic injuries, Drug induce liver injuries
Acute liver disease is characterized by loss of liver function within days or weeks however, in the patient who is not previously diagnosed, its less common compared with chronic liver failure, which developed slowly and irreversible process. It’s caused by
drug-induced liver damage (DILI) therefore identifying liver injury is challenging for clinical treatment and diagnosis. The major causes of liver failure involve toxic metabolites of some medications that consumed Adenosine Tri Phosphate (ATP) compared with normal conditions and increased oxidative stress due to overexpression of MicroRNAs, it is necessary to do complete diagnosis of patients. Biomarker parameters can be utilized to validate liver damage like microRNAs (miRNAs) analysis, it is a more receptive marker because increased earlier than the transaminases enzymes allowing for a more accurate diagnosis. we summarized recent signs of progress disease concerning the role of miRNA as a novel DILI biomarker, the miRNA levels can be measured in plasma, saliva, urine, fetal fluid (amniotic), as well as other materials either in human or animals like mice, rats which significantly elevate during illness, therefore, provide e specific biomarker of hepatoinjury.
- Wang W. Shi Q. Mattes WB. Mendrick DL. Yang X. Translating extracellular microRNA into clinical biomarkers for drug-induced toxicity: from high-throughput profiling to validation. Biomarkers in medicine. 2015 Nov;9(11):1177-1188.
- Howell L. Ireland L. Park B. Goldring, C. MiR-122 and other microRNAs as potential circulating biomarkers of drug-induced liver injury. Expert Rev. Mol. Diagn. 2018: 18 (1); 47–54.
- Aithal G. Ramsay L. Daly A. Sonchit N. Leathart J. Alexander G. et al. Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatol. Baltim. Md.2014; 39 (5): 1430–1440.
- Andrade RJ. Chalasani N.Björnsson ES. Suzuki A. Kullak-Ublick GA. et.al. Drug-induced liver injury. Nature Reviews Disease Primers. 2019 Aug 22;5(1):1-22.
- Lucy M. Dominique L. Drug-Induced Liver Injury: Biomarkers, Requirements, Candidates, and Validation. Front Pharmacol. 2019; 10: 1482.
- Fontana R. J.. Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives.Gastroenterology. 2014 ;146(4), 914–928.
- Reuben A. Koch D. Lee W. Grp ALFS. Drug-Induced Acute Liver Failure: Results of a U.S. Multicenter, Prospective Study. Hepatology. 2010; 52: 2065–2076.
- Yuping W. Tao C. Weida T. miRNAs and their application in drug-induced liver injury. Biomarkers in medicine. 2014; 8(2): 161-72.
- Li-Min L. Dong W. Ke Z.MicroRNAs in Drug-induced Liver Injury. J Clin Transl Hepatol. 2014; 2(3): 162–169.
- Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacology & therapeutics. 2013 Apr 1;138(1):103-141.
- Sun H. Jiang C. Cong L.Wu N. Wang X. et.al. CYP24A1 Inhibition facilitates the antiproliferative effect of 1, 25 (OH) 2D3 through downregulation of the WNT/β-Catenin pathway and methylation-mediated regulation of CYP24A1 in colorectal cancer cells. DNA and Cell Biology. 2018 Sep 1;37(9):742-9.
- Yokoi T. Nakajima M. Toxicological implications of modulation of gene expression by microRNAs. Toxicol Sci. 2011; 123:1–14.
- Aithal G. P. Watkins P. B. Andrade R. J. Larrey D. Molokhia, M. Takikawa H. et al. Case definition and phenotype standardization in drug-induced liver injury. Clin. Pharmacol. Ther.2011; 89 (6): 806–815.
- Cirulli E. T. Nicoletti, P. Abramson K. Andrade, R. J. Bjornsson, E. S. Chalasani, N. et al. Drug-induced liver injury network (DILIN) investigators, International DILI consortium (idyllic), 2019. A missense variant in PTPN22 is a risk factor for drug-induced liver injury. Gastroenterology.2019: 156 (6): 1707–1716.
- Garcia-Cortes M. Robles-Diaz M. Stephens C. Ortega-Alonso A. Lucena MI. Drug induced liver injury: an update. Archives of Toxicology. 2020 Oct;94(10):3381-407.
- Fontana R. J. Watkins P. B. Bonkovsky H. L. Chalasani N. Davern T. Serrano J. et al. Drug-induced liver injury network (DILIN) prospective study: rationale, design, and conduct. Drug Saf. 2009; 32 (1): 55–68.
- Larrey D. Meunier L. Valla D. Hillaire S. Hernandez-Gea V. et.al. Drug induced liver injury and vascular liver disease. Clinics and Research in Hepatology and Gastroenterology. 2020 Sep 1;44(4):471-479.
- Watkins P. B. Desai M. Berkowitz. S. D. Peters. G. Horsmans Y. Larrey D. et al. Evaluation of drug-induced serious hepatotoxicity (Swedish): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery. Drug Saf. 2011;34 (3): 243–252.
- Teschke, R. Larrey D. Melchart D., Danan G. Traditional Chinese Medicine (TCM) and Herbal Hepatotoxicity: Rucam and the role of novel diagnostic biomarkers such as MicroRNAs. Med. Basel.2016; 3(3):18.
- Noor W. Kadhim Al. Abbas M. Effect of human insulin and insulin analog on some inflammatory markers and total antioxidant capacity in a sample of Iraqi type 1 diabetic children and adolescents. Al Mustansiriyah Journal of Pharmaceutical Sciences. 2021; 21(2):9-14.
- Israa B. Aseel G. diagnostic efficiency of Alpha Feto Protein, Hypothyroidism in Thalassemic patients with Liver Damage. Research J. Pharm. and Tech. 2019; 12(12): 5841-5844.